8-K: Azenta Reports Strong Q4, FY25 Results; FY26 Outlook Positive

Azenta, Inc. announced robust financial results for the fourth quarter and full fiscal year 2025, driven by Multiomics growth and significant Adjusted EBITDA margin expansion, with a positive outlook for fiscal 2026.

Summary

• Reported revenue for the fourth quarter of fiscal 2025 was $159 million, a 6% increase year over year, with organic revenue growth of 4%.
• Full year fiscal 2025 reported revenue reached $594 million, up 4% year over year, with organic revenue growth of 3%.
• Adjusted EBITDA margin for fiscal 2025 expanded by 310 basis points compared to the prior year, reaching 11.2%.
• Diluted EPS from continuing operations was $1.11 for Q4 2025, a significant improvement from ($0.04) in Q4 2024.
• Full year diluted EPS from continuing operations was $0.52, up from ($0.46) in fiscal 2024.
• The Multiomics segment demonstrated strong performance, with 11% revenue growth in Q4 2025 (10% organic) and 6% growth in FY 2025 (5% organic), primarily driven by Next Generation Sequencing and Gene Synthesis.
• The company ended fiscal year 2025 with a total balance of cash, cash equivalents, restricted cash, and marketable securities of $546 million.
• For fiscal year 2026, Azenta expects organic revenue growth in the range of 3% to 5% and Adjusted EBITDA margin expansion of approximately 300 basis points.

Sentiment

Score: 8

Explanation: The company reported strong revenue growth, significant Adjusted EBITDA margin expansion, and a substantial improvement in EPS from continuing operations for both the quarter and the full fiscal year. Management's comments indicate a successful "transformative year" and a positive outlook for fiscal 2026 with continued growth and margin expansion. The one-time tax benefit also boosted GAAP EPS.

Positives

• Strong Q4 2025 reported revenue growth of 6% year over year and 4% on an organic basis.
• Solid FY 2025 reported revenue growth of 4% and 3% on an organic basis.
• Significant FY 2025 Adjusted EBITDA margin expansion of 310 basis points, reaching 11.2%.
• Multiomics segment showed robust growth: 11% in Q4 2025 (10% organic) and 6% in FY 2025 (5% organic), driven by Next Generation Sequencing and Gene Synthesis.
• Diluted EPS from continuing operations significantly improved to $1.11 in Q4 2025 (from -$0.04) and $0.52 in FY 2025 (from -$0.46).
• Operating margin improved by 430 basis points year over year in Q4 2025 to 1.2%.
• Gross margin improved by 110 basis points year over year in FY 2025 to 45.5%.
• Operating expenses decreased by 4% in Q4 2025 and 3% in FY 2025, driven by cost discipline and lower charges.
• A one-time $45.6 million tax benefit was recognized related to a worthless stock deduction on a foreign subsidiary.
• Positive outlook for FY 2026 with expected organic revenue growth of 3% to 5% and approximately 300 basis points of Adjusted EBITDA margin expansion.
• Management highlighted a 'transformative year' with simplified organization, progress with the Azenta Business System, and strengthened execution.
• Expectation of higher free cash flow generation in FY 2026.

Negatives

• Sample Management Solutions organic revenue was flat in Q4 2025, mainly due to lower revenue in Cryogenic Systems.
• Sanger sequencing revenue declined year-over-year in both Q4 2025 and FY 2025.
• Adjusted gross margin in Q4 2025 was down 20 basis points year over year, reflecting higher costs and lower volumes in parts of the Multiomics segment.
• Adjusted operating expenses in Q4 2025 were up 4% year over year, primarily due to higher selling, general and administrative expenses and higher research and development costs.
• Net interest income decreased from $6 million in Q4 2024 to $5 million in Q4 2025, and from $33 million in FY 2024 to $19 million in FY 2025.
• Operating loss for the full year was $27 million.
• Total diluted EPS for FY 2025 was negative ($1.30).
• Loss from discontinued operations was significant: ($3.716 million) in Q4 2025 and ($83.161 million) in FY 2025.
• An immaterial classification error was identified in previously issued financial statements, and management is evaluating its impact on the effectiveness of the Company's internal control over financial reporting.

Risks

• Uncertainties in global political and economic conditions, including the imposition of additional tariffs on goods imported into the US.
• Ability to reduce costs effectively.
• Volatility of the life sciences markets the Company serves.
• Possible inability to meet demand for products due to difficulties in obtaining components and materials from suppliers in required quantities and of required quality.
• Inability of customers to make payments when due.
• Price competition.
• Disputes concerning intellectual property.
• Management is evaluating the impact of the classification error on the effectiveness of the Company's internal control over financial reporting.

Future Outlook

For fiscal year 2026, Azenta expects total organic revenue to grow in the range of 3% to 5% year over year. Adjusted EBITDA margin expansion is anticipated to be approximately 300 basis points relative to fiscal 2025, with expectations for higher free cash flow generation.

Management Comments

• "Fiscal 2025 was a transformative year for Azenta. We achieved 3% core revenue growth and meaningful margin expansion." John Marotta, President and Chief Executive Officer.
• "We simplified our organization, made significant progress enabled by the Azenta Business System, and strengthened our execution, which is driving measurable improvements in quality, delivery, and productivity." John Marotta.
• "We enter fiscal 2026 in a healthier position, with a more streamlined and accountable structure, with sharper focus on the customer, and growing momentum across the business." John Marotta.
• "We expect core growth between 3% and 5%, approximately 300 basis points of adjusted EBITDA margin expansion, and higher free cash flow generation." John Marotta.

Industry Context

Azenta operates in the life sciences sector, providing cold-chain sample management and multiomics services. The growth in Multiomics, particularly Next Generation Sequencing, aligns with broader industry trends of increasing demand for advanced genomic research and personalized medicine. The flat organic growth in Sample Management Solutions, specifically lower revenue in Cryogenic Systems, might indicate some market saturation or competitive pressures in certain sub-segments, while growth in Clinical Biostores and Automated Stores suggests continued demand for efficient sample handling in clinical and research settings. The focus on cost reduction and productivity improvement reflects a common industry theme amidst economic uncertainties.

Stakeholder Impact

• Shareholders: Positive financial results, improved EPS, and positive FY 2026 guidance could lead to increased shareholder value. The one-time tax benefit also positively impacts earnings. The evaluation of internal control effectiveness could be a concern.
• Employees: "Simplified our organization" and "strengthened our execution" could imply efficiency gains, potentially impacting workforce structure, though not explicitly stated.
• Customers: "Sharper focus on the customer" and "measurable improvements in quality, delivery, and productivity" suggest improved customer experience.
• Suppliers: "Difficulties in obtaining components and materials from our suppliers" is a risk, indicating potential supply chain challenges.
• Creditors: Improved financial health and cash position ($546 million cash and equivalents) suggest stronger ability to meet obligations.

Next Steps

• Further information regarding the classification error revisions will be provided in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025.
• Management will webcast its fourth quarter and full year fiscal 2025 earnings conference call on November 21, 2025, at 8:30 a.m. Eastern Time.

Key Dates

Recommendation

Azenta delivered robust financial performance in fiscal 2025, marked by solid revenue growth and substantial Adjusted EBITDA margin expansion, significantly improving profitability from the prior year. The Multiomics segment, a key growth driver, continues to perform well. Management's positive outlook for fiscal 2026, projecting continued organic revenue growth and further margin expansion, coupled with expected higher free cash flow generation, indicates strong operational momentum and strategic execution. The company's healthy cash position further strengthens its financial stability. While there was an immaterial classification error, the overall trajectory and guidance suggest a compelling investment opportunity.

Keywords

Life Sciences, Sample Management, Multiomics, Next Generation Sequencing, Gene Synthesis, Financial Results, Earnings, EBITDA, Revenue, Fiscal Year 2025, Fiscal Year 2026, Azenta, AZTA, Biotechnology, Cold Chain, Lab Automation